*Licence 1: Aptamer has received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific application area.

This 10-year licensing deal, which is at an advanced stage of negotiation, is forecast to cover approximately 15% of the Group's annual overhead through passive income over the next three years.

*Licence 2: Aptamer continues to advance licensing discussions with a second partner, a growing global distributor of enzymes.

*Licence 3: Aptamer has further signed a Material Transfer Agreement (MTA) with a third partner, a leading global distributor of enzymes, to allow this partner to evaluate the technology.

RECOMMENDED READING:

Aptamer has also announced a further agreement where Optimer binders are in a final development stage to create products that inhibit enzymes.

And in a second evaluation, Aptamer also reports 'extremely positive feedback' from a major pharmacy company also using Optimer® binders in a clinical drug development programme.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said: "The progress across our enzyme modulation projects, including the advancement to the final development stage on our second inhibitor, is a really exciting milestone.

"The sales forecasts for our first commercial enzyme highlight the tangible value our Optimer® platform can deliver, potentially covering a meaningful portion of the Group's overhead through royalty income.

"With an MTA now in place with a major global distributor, we are well-positioned for additional non-exclusive licenses.

Dr Tolley continued: "With growing commercial interest from global partners, including one of the world's top five pharmaceutical companies, we are confident that our Optimer® platform is well-positioned to deliver long-term shareholder value through recurring royalty revenues and strategic licensing opportunities."